<DOC>
	<DOCNO>NCT02803229</DOCNO>
	<brief_summary>The propose protocol double-blind , placebo-controlled outpatient study safety benefit Extended-release mixed amphetamine salt ( Adderall-XR , MAS-XR ) treatment individual Cannabis Use Disorder ( CUD ) Attention-deficit/Hyperactivity Disorder ( ADHD ) . The investigator plan enroll 50 randomize 40 patient trial . The primary objective study determine efficacy MAS-XR promoting cannabis abstinence among individual CUD promote decrease ADHD symptom .</brief_summary>
	<brief_title>Treatment Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description>ADHD common substance use disorder patient general cannabis use disorder ( CUD ) particular , occur rate substantially great general population . A meta-analysis find approximately 23 % substance abuser seek treatment childhood and/or adult ADHD . Moreover , ADHD overrepresented adult CUD compare substance use disorder patient seek treatment . The importance treat CUD individual also ADHD underscore finding demonstrate individual co-occurring ADHD substance use disorder particularly intractable group : exhibit earlier onset use , severe use , complicate pattern remission/relapse , poorer treatment outcomes relative without ADHD . Yet , date , ADHD individual CUD adequately study . The investigator find treatment research study target cannabis dependence substantial percentage ( 35 % ) screen positive adult ADHD , rate higher participant cocaine use disorder clinical trial almost 8x great rate find general population . Thus , appear sizable cannabis-abusing group warrant much great clinical attention currently receive . The goal demonstrate feasibility , tolerability , estimate effect size purpose plan future definitive trial . Because research team 's extensive experience work stimulant medication treat ADHD cocaine-dependent population , large effect size amphetamine treat adult ADHD , notable reduction cocaine use ADHD symptoms cocaine-dependent ADHD adult , investigator explore efficacy Adderall-XR ( MAS-XR ) treatment cannabis use disorder ADHD . The study 12 week placebo control double-blind trial . The maximum maintain dose 80 mg MAS-XR daily .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>Individuals meet criterion cannabis use disorder ( CUD ) report marijuana primary drug abuse Individuals must report use marijuana least 5 day week past 28 day positive urine test THC day study entry Individuals must meet DSM5 criterion adult ADHD Individuals score &gt; 22 AISRS scale Individuals age 1865 capable give informed consent capable comply study procedure Women childbearing age include : ) pregnant , b ) agree use effective method contraception , c ) agree become pregnant study ) breastfeeding . To confirm , urine pregnancy test repeat every month screen . Women provide full explanation potential danger pregnancy take MASXR . If woman become pregnant , take medication continue standard treatment STARS . At end study , patient offer treatment STARS appropriate referral make community clinic . Individuals meet DSM5 criterion schizophrenia , schizoaffective illness , psychotic disorder transient psychosis due drug abuse , current major depression , bipolar illness psychiatric disorder ( substance abuse ) require psychiatric intervention would interfere study participation Individuals medically unstable base laboratory test , electrocardiogram , medical history , physical examination would make participation hazardous Use synthetic cannabinoids past month meeting CUD diagnosis base synthetic cannabinoids use alone past year Individuals liver enzyme function test great 3 time normal Individuals significant current suicidal risk Individuals systolic blood pressure &gt; 140 ; diastolic blood pressure &gt; 90 ; pulse &gt; 100 Individuals cognitively impair impede study participation Nursing mother pregnant woman Individuals physiologically dependent drug ( exclude nicotine ) would require medical intervention Individuals know sensitivity/allergy MASXR amphetamine analog Individuals currently prescribe psychotropic medication ( include sleep medication ) Individuals history seizure Individuals mandate treatment Individuals history amphetamine use disorder , include amphetamine methamphetamine MDMA . Individuals current cocaine use disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>